Skip to main
DRTS

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical is a clinical-stage oncology therapeutics company with a proprietary technology utilizing alpha particles for targeted radiation therapy in a variety of solid tumor types. The company's active clinical programs and geographical diversification offer potential for long-term growth, while recent data from U.S. regulatory trials and promising interim results in recurrent glioblastoma reinforce the potential efficacy of their treatment. Additionally, the company's cash runway through 2027 provides a solid financial foundation for continued development and potential expansion into new indications.

Bears say

Alpha Tau Medical is a clinical-stage oncology therapeutics company with a focused proprietary technology designed to overcome the traditional limitations of alpha radiation. While the company has active clinical programs targeting various tumor types and has received FDA approval for expansion of its pancreatic cancer pilot trial, the company's topline data for its pivotal ReSTART trial is not expected until the end of 2026. The company's valuation is estimated to be $1.30B, with a 12-month price target of $15 per share and potential risks include the failure of Alpha DaRT to secure regulatory approval and achieve commercial success.

DRTS has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Buy based on their latest research and market trends.

According to 5 analysts, DRTS has a Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.